Litcius/Paper detail

Biologic Therapies for Severe Asthma

Guy G. Brusselle, Gerard H. Koppelman

2022New England Journal of Medicine686 citationsDOIOpen Access PDF

Abstract

Patients with severe asthma are at increased risk for a decreased quality of life, fixed airway obstruction, hospitalization, and death. Biologics may be required to reduce the disease burden. This review discusses the mechanisms, efficacy, and safety of biologics for severe asthma.

Topics & Concepts

MedicineAsthmaIntensive care medicineDiseaseAirwayQuality of life (healthcare)Respiratory diseaseImmunologyClinical trialAdrenergic beta-AgonistsInternal medicineBiologic AgentsAcute severe asthmaMEDLINEOmalizumabBronchodilator AgentsInhaled corticosteroidsAsthma and respiratory diseasesDermatology and Skin DiseasesRespiratory and Cough-Related Research